[{"orgOrder":0,"company":"Synlogic","sponsor":"Ginkgo Bioworks","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Synlogic Announces Synthetic Biotic for Gout Developed in Partnership with Ginkgo Bioworks","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Large molecule","productStatus":"New Molecular Entity","date":"August 2022","url1":"","url2":"","graph1":"Large molecule","graph2":"Synlogic"},{"orgOrder":0,"company":"Jiangsu Atom Bioscience & Pharmaceutical","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Atom Bioscience Receives FDA IND Clearance for Clinical Trial of ABP-745 for Acute Gout","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"IND Enabling","country":"CHINA","productType":"Small molecule","productStatus":"New Molecular Entity","date":"January 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Jiangsu Atom Bioscience & Pharmaceutical"},{"orgOrder":0,"company":"PK MED","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"PK MED Announces FDA Clearance to Initiate Its Clinical Program for PKM-01, for Local Treatment of Gout Flares, Directly by a Phase 2 Trial","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"IND Enabling","country":"FRANCE","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"PK MED"},{"orgOrder":0,"company":"Monte Rosa Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Monte Rosa Therapeutics Announces Initiation of IND Enabling Studies for MRT-8102, A First-in-Class NEK7 Directed Molecular Glue Degrader and NLRP3\/IL-1\u03b2 Pathway Inhibitor","therapeuticArea":"Rheumatology","highestDevelopmentStatus":"IND Enabling","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2024","url1":"","url2":"","graph1":"Small molecule","graph2":"Monte Rosa Therapeutics"}]
Find Clinical Drug Development Pipelines & Deals | PipelineProspector
MRT-8102 is a first-in-class NEK7 directed molecular glue degrader and NLRP3/IL-1β pathway inhibitor, which is being evaluated for the treatment of multiple inflammatory diseases, including gout, pericarditis and other cardiovascular diseases.
PKM-01 (colchicine) is an intra-articular combination of a fast-acting anesthetic and a controlled-release form of a powerful anti-inflammatory agent (colchicine). It is being evaluated for the treatment of gout flares.
ABP-745 is an oral small molecule drug which is being evaluated for the treatment of acute gout. Preclinical trials showed that it can significantly reduce levels of inflammatory factors & compared with similar drugs, it has good efficiency & significant safety improvement.
The new candidate, SYNB2081, is a Synthetic Biotic and is the second product to advance to clinical development through a research collaboration between Synlogic and Ginkgo, following investigational new drug candidate SYNB1353 for the potential treatment of homocystinuria.